Cargando…

The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: where is the clinically relevant hotspot for prostate cancer?

Detalles Bibliográficos
Autores principales:	Matsumoto, Takashi, Shiota, Masaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658146/ https://www.ncbi.nlm.nih.gov/pubmed/33209696 http://dx.doi.org/10.21037/tau-20-866

Ejemplares similares

Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Rebbeck, Timothy R, et al.
Publicado: (2008)

Editorial Comment to Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification
por: Matsumoto, Takashi, et al.
Publicado: (2021)

Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis
por: Edwards, S M, et al.
Publicado: (2010)

Broccoli, PTEN deletion and prostate cancer: where is the link?
por: Appendino, Giovanni, et al.
Publicado: (2010)

Discussion on the use of taxanes for treatment of breast cancers in BRCA1 mutations carriers
Publicado: (2007)

RANKL/OPG in Breast Cancer — Extending Its Territory to BRCA Mutation Carriers
por: Rachner, Tilman D., et al.
Publicado: (2015)

An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)
por: Chenevix-Trench, Georgia, et al.
Publicado: (2007)

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype
por: Mitra, A, et al.
Publicado: (2008)

RAD52 S346X variant reduces breast cancer risk in BRCA2 mutation carriers
por: Biswas, Kajal, et al.
Publicado: (2020)

Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores
por: Lecarpentier, Julie, et al.
Publicado: (2017)

Prostate screening uptake in Australian BRCA1 and BRCA2 carriers
por: McKinley, Joanne M, et al.
Publicado: (2007)

Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
por: Bancroft, Elizabeth K., et al.
Publicado: (2014)

Prostate Cancer Risks for Male BRCA1 [Image: see text] and BRCA2 Mutation Carriers: A Prospective Cohort Study()
por: Nyberg, Tommy, et al.
Publicado: (2020)

Risk stratification tools in prostate cancer, where do we stand?
por: Clinckaert, Andries, et al.
Publicado: (2021)

Mutations in BRCA2 and taxane resistance in prostate cancer
por: Nientiedt, Cathleen, et al.
Publicado: (2017)

BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications
por: Messina, Carlo, et al.
Publicado: (2020)

BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored
por: Crocetto, Felice, et al.
Publicado: (2021)

BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside
por: Boussios, Stergios, et al.
Publicado: (2022)

Characteristics of BRCA2 Mutated Prostate Cancer at Presentation
por: Han, Hyunho, et al.
Publicado: (2022)

Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician’s Perspective
por: Matsumoto, Takashi, et al.
Publicado: (2022)

The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers
por: Cavanagh, Helen, et al.
Publicado: (2015)

Breast cancer therapy for BRCA1 carriers: moving towards platinum standard?
por: Imyanitov, Evgeny N
Publicado: (2009)

5-α reductase inhibitors and prostate cancer prevention: where do we turn now?
por: Hamilton, Robert J, et al.
Publicado: (2011)

Germline BRCA1 mutations increase prostate cancer risk
por: Leongamornlert, D, et al.
Publicado: (2012)

Analysis of BRCA Germline Mutations in Chinese Prostate Cancer Patients
por: Chen, Wei, et al.
Publicado: (2022)

BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations
por: Shah, Sidrah, et al.
Publicado: (2021)

Potential Excess Mortality in BRCA1/2 Mutation Carriers beyond Breast, Ovarian, Prostate, and Pancreatic Cancers, and Melanoma
por: Mai, Phuong L., et al.
Publicado: (2009)

Ambiguity in a masculine world: Being a BRCA1/2 mutation carrier and a man with prostate cancer
por: Moynihan, C., et al.
Publicado: (2017)

Cancer risks among BRCA1 and BRCA2 mutation carriers
por: Levy-Lahad, E, et al.
Publicado: (2007)

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)

Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer
por: Warner, Ellen
Publicado: (2018)

The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel
por: Vazina, A, et al.
Publicado: (2000)

Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations
por: Bancroft, Elizabeth K., et al.
Publicado: (2018)

Optimizing recruitment to a prostate cancer surveillance program among male BRCA1 mutation carriers: invitation by mail or by telephone
por: Galor, Anna, et al.
Publicado: (2013)

Looking for BRCA1 and BRCA2 mutations in Asian women with breast cancer
por: Narod, Steven A.
Publicado: (2023)

Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores
por: Barnes, Daniel R, et al.
Publicado: (2021)

The Role of Nuclear Receptors in Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2019)

Rapid progression of prostate cancer in men with a BRCA2 mutation
por: Narod, S A, et al.
Publicado: (2008)

The BRCA2 mutation status shapes the immune phenotype of prostate cancer
por: Jenzer, Maximilian, et al.
Publicado: (2019)

Risks of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ahmed, M, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_77qdgt001mncj5okecam786t0b